December 20, 2019
December 20, 2019 – The U.S. FDA has approved Enhertu® (fam-trastuzumab deruxtecan-nxki),
manufactured by Daiichi Sankyo, to treat adult patients who have unresectable or metastatic HER2-
positive breast cancer and have been treated with at least two prior anti-HER2-based regimens in the